Anavex Life Sciences Corp. (AVXL) vs Sutro Biopharma, Inc. (STRO)

A side-by-side comparison of Anavex Life Sciences Corp. and Sutro Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — AVXL vs STRO

growth of $100 · dividends reinvested · last 8y
AVXL -43.1% (-6.8%/yr)STRO -90.0% (-25.1%/yr)AVXL compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $1002020202220242026$57$10
AVXL STRO

AVXL vs STRO: by the numbers

  • •AVXL is the larger company ($146M vs $140M market cap).
  • •Both run net losses; AVXL's is the smaller (0.00% vs -395.25% net margin).

Metrics side by side

Valuation

MetricAVXLSTRO
P/S ratioN/A3.06
P/B ratio1.30N/A

Profitability

MetricAVXLSTRO
Gross margin0.00%97.20%
Operating margin0.00%-102.41%
Net margin0.00%-395.25%
ROE-21.38%N/A
ROIC-27.25%-100.04%

Growth (annualized)

MetricAVXLSTRO
Revenue CAGR (5Y)N/A19.13%
Total return CAGR (5Y)-37.74%-39.51%

Frequently asked

How have AVXL and STRO total returns compared?
Over the past 5 years, AVXL delivered -37.74% and STRO delivered -39.51% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.